Wells Fargo & Co reissued their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research report report published on Wednesday.

Several other research analysts have also commented on JAZZ. Cantor Fitzgerald reaffirmed a buy rating and set a $201.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday. BidaskClub lowered shares of Jazz Pharmaceuticals from a sell rating to a strong sell rating in a research note on Wednesday, September 19th. Morgan Stanley lowered shares of Jazz Pharmaceuticals from an overweight rating to an equal weight rating and set a $183.00 price objective for the company. in a research note on Wednesday, July 11th. Zacks Investment Research lowered shares of Jazz Pharmaceuticals from a hold rating to a sell rating in a research note on Monday, July 16th. Finally, Leerink Swann lifted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $210.00 and gave the stock an outperform rating in a research note on Friday, August 17th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and fourteen have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $191.94.

Shares of JAZZ stock traded up $3.38 on Wednesday, reaching $145.57. The company’s stock had a trading volume of 1,051,546 shares, compared to its average volume of 631,079. Jazz Pharmaceuticals has a 1 year low of $130.15 and a 1 year high of $184.00. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.62 and a current ratio of 4.29. The firm has a market cap of $8.47 billion, a PE ratio of 15.23, a price-to-earnings-growth ratio of 0.76 and a beta of 1.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share for the quarter, beating analysts’ consensus estimates of $3.32 by $0.26. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The firm had revenue of $469.37 million during the quarter, compared to analyst estimates of $482.64 million. During the same period last year, the firm posted $3.22 earnings per share. Jazz Pharmaceuticals’s revenue for the quarter was up 14.0% compared to the same quarter last year. On average, equities analysts predict that Jazz Pharmaceuticals will post 11.71 EPS for the current year.

In related news, CFO Matthew P. Young sold 700 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, August 15th. The stock was sold at an average price of $176.05, for a total value of $123,235.00. Following the completion of the sale, the chief financial officer now directly owns 34,168 shares in the company, valued at $6,015,276.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Patrick G. Enright sold 10,130 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $168.76, for a total value of $1,709,538.80. Following the completion of the sale, the director now owns 19,884 shares of the company’s stock, valued at $3,355,623.84. The disclosure for this sale can be found here. Insiders have sold 16,730 shares of company stock valued at $2,796,532 over the last three months. Insiders own 3.90% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in JAZZ. Stratos Wealth Partners LTD. bought a new stake in shares of Jazz Pharmaceuticals in the third quarter valued at about $106,000. Tiverton Asset Management LLC bought a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at about $198,000. Moloney Securities Asset Management LLC bought a new position in Jazz Pharmaceuticals in the second quarter worth about $204,000. FDx Advisors Inc. bought a new position in Jazz Pharmaceuticals in the second quarter worth about $244,000. Finally, Cadence Capital Management LLC bought a new position in Jazz Pharmaceuticals in the third quarter worth about $263,000. Hedge funds and other institutional investors own 92.95% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

See Also: Why do companies engage in swaps?

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.